Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kian, Waleed, Christopoulos, Petros, Remilah, Areen A., Levison, Esther, Dudnik, Elizabeth, Shalata, Walid, Krayim, Bilal, Marei, Ranin, Yakobson, Alexander, Faehling, Martin, Kahala, Dolev, Sara Granot, Inbal, Levitas, Dina, Peled, Nir, Roisman, Laila C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531269/
https://www.ncbi.nlm.nih.gov/pubmed/36203432
http://dx.doi.org/10.3389/fonc.2022.1010311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531269/
https://www.ncbi.nlm.nih.gov/pubmed/36203432
http://dx.doi.org/10.3389/fonc.2022.1010311

Ejemplares similares